BACKGROUND: Recently, serum 25-hydroxyvitamin D (25OHD) levels were shown to be associated with the survival of patients with colorectal cancer. However, 25OHD levels were measured a median of 6 years before diagnosis or were predicted levels. In this study, we directly measured serum 25OHD levels at surgery and examined the association with survival among patients with colorectal cancer. METHODS: We started a prospective cohort study to find prognostic factors in patients with colorectal cancer from 2003 to 2008 and stored serum samples and clinical data. As part of a post-hoc analysis, serum 25OHD levels were measured by radioimmunoassay. Association between overall survival and serum 25OHD levels were computed using the Cox proportional hazard model adjusted for month of serum sampling as well as age at diagnosis, gender, cancer stage, residual tumor after surgery, time period of surgery, location of tumor, adjuvant chemotherapy and number of lymph nodes with metastasis at surgery. Unadjusted and adjusted hazard ratios (HR) and 95% confidence intervals (95% CI) were determined. RESULTS: Serum 25OHD levels were measured in 257 patients. Only 3% had sufficient levels (30 ng/ml and greater). Based on month of blood sampling, an annual oscillation of 25OHD levels was seen, with levels being lower in spring and higher in late summer. Higher 25OHD levels were associated with better overall survival under multi-variate analysis (HR, 0.91: 95% CI, 0.84 to 0.99, P = 0.027). CONCLUSIONS: These results suggest that higher 25OHD levels at surgery may be associated with a better survival rate of patients with colorectal cancer.
BACKGROUND: Recently, serum 25-hydroxyvitamin D (25OHD) levels were shown to be associated with the survival of patients with colorectal cancer. However, 25OHD levels were measured a median of 6 years before diagnosis or were predicted levels. In this study, we directly measured serum 25OHD levels at surgery and examined the association with survival among patients with colorectal cancer. METHODS: We started a prospective cohort study to find prognostic factors in patients with colorectal cancer from 2003 to 2008 and stored serum samples and clinical data. As part of a post-hoc analysis, serum 25OHD levels were measured by radioimmunoassay. Association between overall survival and serum 25OHD levels were computed using the Cox proportional hazard model adjusted for month of serum sampling as well as age at diagnosis, gender, cancer stage, residual tumor after surgery, time period of surgery, location of tumor, adjuvant chemotherapy and number of lymph nodes with metastasis at surgery. Unadjusted and adjusted hazard ratios (HR) and 95% confidence intervals (95% CI) were determined. RESULTS: Serum 25OHD levels were measured in 257 patients. Only 3% had sufficient levels (30 ng/ml and greater). Based on month of blood sampling, an annual oscillation of 25OHD levels was seen, with levels being lower in spring and higher in late summer. Higher 25OHD levels were associated with better overall survival under multi-variate analysis (HR, 0.91: 95% CI, 0.84 to 0.99, P = 0.027). CONCLUSIONS: These results suggest that higher 25OHD levels at surgery may be associated with a better survival rate of patients with colorectal cancer.
Authors: Edward D Gorham; Cedric F Garland; Frank C Garland; William B Grant; Sharif B Mohr; Martin Lipkin; Harold L Newmark; Edward Giovannucci; Melissa Wei; Michael F Holick Journal: Am J Prev Med Date: 2007-03 Impact factor: 5.043
Authors: Peter R Holt; Nadir Arber; Balazs Halmos; Kenneth Forde; Harry Kissileff; Katherine A McGlynn; Steven F Moss; N Kurihara; K Fan; Kunhua Yang; Martin Lipkin Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-01 Impact factor: 4.254
Authors: Edward Giovannucci; Yan Liu; Eric B Rimm; Bruce W Hollis; Charles S Fuchs; Meir J Stampfer; Walter C Willett Journal: J Natl Cancer Inst Date: 2006-04-05 Impact factor: 13.506
Authors: Peter R Holt; Robert S Bresalier; Chan K Ma; Kai-Feng Liu; Martin Lipkin; James C Byrd; Kan Yang Journal: Cancer Date: 2006-01-15 Impact factor: 6.860
Authors: Wei Zhou; Rebecca S Heist; Geoffrey Liu; Kofi Asomaning; Donna S Neuberg; Bruce W Hollis; John C Wain; Thomas J Lynch; Edward Giovannucci; Li Su; David C Christiani Journal: J Clin Oncol Date: 2007-02-10 Impact factor: 44.544
Authors: Jean Wactawski-Wende; Jane Morley Kotchen; Garnet L Anderson; Annlouise R Assaf; Robert L Brunner; Mary Jo O'Sullivan; Karen L Margolis; Judith K Ockene; Lawrence Phillips; Linda Pottern; Ross L Prentice; John Robbins; Thomas E Rohan; Gloria E Sarto; Santosh Sharma; Marcia L Stefanick; Linda Van Horn; Robert B Wallace; Evelyn Whitlock; Tamsen Bassford; Shirley A A Beresford; Henry R Black; Denise E Bonds; Robert G Brzyski; Bette Caan; Rowan T Chlebowski; Barbara Cochrane; Cedric Garland; Margery Gass; Jennifer Hays; Gerardo Heiss; Susan L Hendrix; Barbara V Howard; Judith Hsia; F Allan Hubbell; Rebecca D Jackson; Karen C Johnson; Howard Judd; Charles L Kooperberg; Lewis H Kuller; Andrea Z LaCroix; Dorothy S Lane; Robert D Langer; Norman L Lasser; Cora E Lewis; Marian C Limacher; JoAnn E Manson Journal: N Engl J Med Date: 2006-02-16 Impact factor: 91.245
Authors: T Kobayashi; T Okano; S Shida; K Okada; T Suginohara; H Nakao; E Kuroda; S Kodama; T Matsuo Journal: J Nutr Sci Vitaminol (Tokyo) Date: 1983-06 Impact factor: 2.000
Authors: K Ng; B M Wolpin; J A Meyerhardt; K Wu; A T Chan; B W Hollis; E L Giovannucci; M J Stampfer; W C Willett; C S Fuchs Journal: Br J Cancer Date: 2009-08-18 Impact factor: 7.640
Authors: Kathleen M Wesa; Neil H Segal; Angel M Cronin; Daniel D Sjoberg; Gria N Jacobs; Marci I Coleton; Martin Fleisher; Ann M Dnistrian; Leonard B Saltz; Barrie R Cassileth Journal: Nutr Cancer Date: 2015-02-03 Impact factor: 2.900
Authors: Steinar Tretli; Gary G Schwartz; Peter Abusdal Torjesen; Trude Eid Robsahm Journal: Cancer Causes Control Date: 2011-12-23 Impact factor: 2.506
Authors: Jeffrey A Meyerhardt; Kimmie Ng; Chen Yuan; Kaori Sato; Bruce W Hollis; Sui Zhang; Donna Niedzwiecki; Fang-Shu Ou; I-Wen Chang; Bert H O'Neil; Federico Innocenti; Heinz-Josef Lenz; Charles D Blanke; Richard M Goldberg; Alan P Venook; Robert J Mayer; Charles S Fuchs Journal: Clin Cancer Res Date: 2019-09-23 Impact factor: 12.531
Authors: Katherine Van Loon; Devin Wigler; Donna Niedzwiecki; Alan P Venook; Charles Fuchs; Charles Blanke; Leonard Saltz; Richard M Goldberg; Jeffrey A Meyerhardt Journal: Clin Colorectal Cancer Date: 2013-01-12 Impact factor: 4.481